Posted by Michael Wonder on 27 Dec 2021
FDA approves add-on therapy to lower cholesterol among certain high-risk adults
22 December 2021 - FDA has approved Leqvio (inclisiran) injection as a treatment to be used along with diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolaemia or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol.
The effectiveness of Leqvio was studied in three randomised, double-blind, placebo-controlled trials that enrolled 3,457 adults with heterozygous familial hypercholesterolaemia or clinical atherosclerotic cardiovascular disease.
